Physician profile
Jacqueline Sutter
NPI 1417113325
$188,989.49
in general payments reported to CMS, 2019-2025
40 companies · $48K in 2025
The $48K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $7,193 · 2021: $11K · 2022: $3,835 · 2023: $32K · 2024: $63K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $109K · Consulting Fee: $14K · Travel and Lodging: $11K · Food and Beverage: $8,976 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $108,568.70 |
| Consulting Fee | $13,913.50 |
| Travel and Lodging | $11,478.00 |
| Food and Beverage | $8,975.50 |
| Education | $108.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $71,821.32 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50,397.80 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Genzyme Corporation | $31,691.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $27,827.64 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Ani Pharmaceuticals, INC. | $1,478.29 | 2022-2025 | Purified Cortrophin Gel |
| Intuitive Surgical, INC. | $1,321.14 | 2021-2022 | |
| Glaxosmithkline, LLC. | $915.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Ethicon INC. | $846.87 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $371.21 | 2020-2024 | |
| Mylan Specialty L.P. | $303.55 | 2019-2024 | Yupelri |
| Galvanize Therapeutics, INC | $236.62 | 2023-2025 | Aliya System |
| Genentech USA, INC. | $202.51 | 2019-2025 | Xolair |
| Insmed, INC. | $171.10 | 2021-2024 | Arikayce |
| Verona Pharma, INC. | $164.23 | 2025 | Ohtuvayre |
| Abbvie INC. | $139.63 | 2022-2025 | Avycaz, Teflaro |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $111.95 | 2019-2025 | Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $107.45 | 2022-2024 | Aralast |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Pulmonx Corporation | $80.55 | 2019-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Mallinckrodt Hospital Products INC. | $75.90 | 2022 | |
| Covis Pharma Gmbh | $73.36 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $63.71 | 2019-2024 | |
| Electromed, INC. | $59.26 | 2024-2025 | Smartvest |
| Mallinckrodt Enterprises LLC | $51.12 | 2019 | |
| Amgen INC. | $46.87 | 2022-2024 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $37.82 | 2019-2020 | |
| Circassia INC. | $31.70 | 2019 | |
| Inogen, INC. | $27.61 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| United Therapeutics Corporation | $26.16 | 2024 | Tyvaso |
| Viatris Specialty LLC | $23.05 | 2025 | Yupelri |
| Paratek Pharmaceuticals, INC. | $22.10 | 2021 | |
| Vifor Pharma, INC. | $22.03 | 2024 | Zemaira |
| Grifols USA, LLC | $21.49 | 2020 | |
| Alexion Pharmaceuticals, INC. | $21.42 | 2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $21.28 | 2019 | |
| Allergan, INC. | $21.17 | 2020 | |
| Kaleo, INC. | $20.49 | 2019 | |
| Boston Scientific Corporation | $18.79 | 2023 | |
| Merck Sharp & Dohme LLC | $14.95 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Sutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.